skin toxicity caused by EGFR - TKIs in lung adenocarcinoma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: (1) Patients with confirmed pathological diagnosis of malignant lung tumor and EGFR gene exon 19/21 mutations. (2) Aged 18-80 years (inclusive). (3) Patients currently undergoing EGFR-TKIs therapy who have developed drug-related rash. (4) Expected survival period = 3 months. (5) Patients diagnosed with the damp-heat toxin stagnation syndrome pattern. (6) Without severe cardiac hepatic or renal dysfunction. (7) No intellectual disabilities or mental disorders; normal verbal expression ability. (8) Fully understand and voluntarily agree to participate in this clinical study having signed the written informed consent form
Exclusion criteria
Exclusion criteria: (1) Patients with severe cardiovascular or hematopoietic system diseases other severe primary diseases or mental illnesses. (2) Patients currently undergoing hormone therapy or antibiotic treatment. (3) Patients uncooperative during the treatment period (i.e. unable to cooperate to complete all clinical observations). (4) Patients who have recently participated in other clinical trials involving acupuncture. (5) Women who are pregnant planning pregnancy or lactating. (6) Patients with severe needle phobia or blood phobia who cannot tolerate the procedure. (7) Patients planning to undergo acupuncture pricking therapy bloodletting cupping therapy or other disease-related treatments and clinical research trials within the 3-month study participation period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acne-like rash grading score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrence rate of rash;Hamilton Depression Scale;Acne Specific Quality of Life;Total effective rate of rash improvement;Hamilton Anxiety Scale;Karnofsky Performance Status ; | — |
Countries
China
Contacts
First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine